Lindy L. Bancke

发表

Pharmacokinetics, pharmacodynamics, and safety of USL261, a midazolam formulation optimized for intranasal delivery, in a randomized study with healthy volunteers

K. Rodvold, B. Gidal, M. Halvorsen, 2015, Epilepsia.

Pharmacokinetics , pharmacodynamics , and safety of USL 261 , amidazolam formulation optimized for intranasal delivery , in a randomized study with healthy volunteers *

K. Rodvold, B. Gidal, M. Halvorsen, 2015 .

Pharmacokinetics of USL261, a Novel Formulation of Intranasal Midazolam (P02.212)

H. Dworak, Lindy L. Bancke, Mark B. Halvorsen, 2013 .

Safety and Pharmacodynamics of USL261, a Novel Formulation of Midazolam Optimized for Intranasal Administration (P02.211)

H. Dworak, Lindy L. Bancke, Mark B. Halvorsen, 2013 .

Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent Clostridioides difficile Infection in Older Adults With Underlying Comorbidities

Stuart Johnson, P. Feuerstadt, M. Ando, 2022, Open forum infectious diseases.

Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection

S. Khanna, J. Garcia-Diaz, S. Berry, 2022, Drugs.

522. Significant Improvement in Health-Related Quality of Life (HRQL) with RBX2660: Results from a Phase 3 Randomized, Placebo-Controlled Trial in Recurrent Clostridioides Difficile Infection (PUNCH CD3)

K. Garey, E. Dubberke, G. Tillotson, 2022, Open Forum Infectious Diseases.

S838 Health-Related Quality of Life in Patients With One Prior Episode of Recurrent Clostridioides difficile Infection (rCDI): Results from the RBX2660 Phase 3 Randomized, Placebo-Controlled rCDI Trial (PUNCH CD3)

K. Garey, E. Dubberke, A. Guo, 2022, American Journal of Gastroenterology.

S836 Health-Related Quality of Life of Week 8 Responders and Non-Responders: Results from the RBX2660 Phase 3 Randomized, Placebo-Controlled Trial in Recurrent Clostridioides difficile Infection (PUNCH CD3)

K. Garey, E. Dubberke, A. Guo, 2022, American Journal of Gastroenterology.

S208 RBX2660, an Investigational Live Microbiota-based Biotherapeutic, Improves Outcomes of Clostridioides difficile Infection in a Real-World Population: A Retrospective Study of Use Under Enforcement Discretion

P. Feuerstadt, Adam J Harvey, Lindy L. Bancke, 2021, American Journal of Gastroenterology.

Safety of fecal microbiota, live-jslm (REBYOTA™) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials

E. Dubberke, S. Khanna, R. Orenstein, 2023, Therapeutic advances in gastroenterology.

Retrospective Analysis of the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTATM) Administered Under Enforcement Discretion to Patients With Clostridioides difficile Infection

P. Feuerstadt, W. Knapple, Adam J Harvey, 2023, Open forum infectious diseases.

Effect of Fecal Microbiota, Live-Jslm (REBYOTA [RBL]) on Health-Related Quality of Life in Patients With Recurrent Clostridioides difficile Infection: Results From the PUNCH CD3 Clinical Trial

K. Garey, E. Dubberke, G. Tillotson, 2023, Open forum infectious diseases.

Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection

K. Garey, E. Dubberke, J. Allegretti, 2024, Infectious diseases and therapy.